Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance

Jorge J. Castillo, Morie Gertz

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.

Original languageEnglish (US)
Pages (from-to)773-780
Number of pages8
JournalLeukemia and Lymphoma
Volume58
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Waldenstrom Macroglobulinemia
Multiple Myeloma
Acute Myeloid Leukemia
Neoplasms
Paraproteinemias
Lymphoma, Large B-Cell, Diffuse
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thyroid Neoplasms
Melanoma
Survival
Therapeutics

Keywords

  • MGUS
  • Myeloma
  • secondary malignancies
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. / Castillo, Jorge J.; Gertz, Morie.

In: Leukemia and Lymphoma, Vol. 58, No. 4, 03.04.2017, p. 773-780.

Research output: Contribution to journalReview article

@article{366aa11a0f6249db919aacc0eacae724,
title = "Secondary malignancies in patients with multiple myeloma, Waldenstr{\"o}m macroglobulinemia and monoclonal gammopathy of undetermined significance",
abstract = "In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenstr{\"o}m macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.",
keywords = "MGUS, Myeloma, secondary malignancies, Waldenstr{\"o}m macroglobulinemia",
author = "Castillo, {Jorge J.} and Morie Gertz",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/10428194.2016.1217527",
language = "English (US)",
volume = "58",
pages = "773--780",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance

AU - Castillo, Jorge J.

AU - Gertz, Morie

PY - 2017/4/3

Y1 - 2017/4/3

N2 - In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.

AB - In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.

KW - MGUS

KW - Myeloma

KW - secondary malignancies

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84983543808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983543808&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1217527

DO - 10.1080/10428194.2016.1217527

M3 - Review article

VL - 58

SP - 773

EP - 780

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -